Kevin L. Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin L. Du has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Harvey G. Moore
Division of Colon and Rectal Surgery, New York University Langone Medical Center, New York, NY, USA
2 shared publicationsNicholas J. Sanfilippo
Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, USA
2 shared publicationsPing Gu
Division of Hematology and Oncology, New York University Langone Medical Center, New York, NY, USA
2 shared publications- Adam Currey
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication - Akila Ninette Viswanathan
Johns Hopkins University School of Medicine, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, MD
1 shared publication - Alexander Spektor
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- 27 June 2017
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 13 (4) , 276-283
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
- 27 June 2017
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 13 (4) , 276-283
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
- 1 February 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13 (2) , 203-209
Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology
- 1 February 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13 (2) , 203-209
Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology
- Open Access
- 22 December 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 286
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer
Objective: Approximately 10-40% of rectal patients have a complete response (CR) to neoadjuvant chemoradiation (CRT), and these patients have improved survival. Thus, non-operative management (“watch-and-wait” approach) may be an option for select patients. We aimed to identify clinical predictors of complete response following CRT. Methods: Patients treated with definitive chemoradiation for T3-T4, locally unresectable T1-T2, low-lying T2, and/or node-positive rectal cancer from August 2004 to February 2015 were retrospectively reviewed. Most patients were treated with 50.4 Gy radiation and concurrent 5-fluoruracil or capecitabine. Patients were considered to have a CR if surgical pathology revealed ypT0N0M0 (operative management), or if they had no evidence of residual disease on clinical and radiographic assessment (non-operative management). Statistical analysis was carried out to determine predictors of CR and long-term outcomes. Results: Complete records were available on 138 patients. The median follow-up was 24.5 mos. 36 patients (26.3%) achieved a CR; 30/123 operatively managed patients (24.5%) and 6/15 (40%) non-operatively managed patients. None of the 10 patients with mucinous adenocarcinoma achieved a CR. CEA ≥5 μg/L at diagnosis (OR 0.190, 95% CI 0.037-0.971, p=0.046), tumor size ≥3 cm (OR 0.123, 95% CI 0.020-0.745, p=0.023), distance of tumor from the anal verge ≥3 cm (OR 0.091, 95% CI 0.013-0.613, p=0.014), clinically node positive disease at diagnosis (OR 0.201, 95% CI 0.045-0.895, p=0.035), and interval from CRT to surgery ≥8 weeks (OR 5.267, 95% CI 1.068-25.961, p=0.041) were independent predictors of CR. The CR group had longer 3-year distant metastasis-free survival (DMFS) (93.7% vs. 63.7%, p=0.016) and 3-year disease-free survival (DFS) (91.1% vs. 67.8%, p=0.038). 3-year locoregional control (LRC) (96.6% vs. 81.3%, p=0.103) and overall survival (OS) (97.2% vs. 87.5%, p=0.125) were higher in the CR group but this did not achieve statistical significance. CR was not an independent predictor of LRC, DMFS, or DFS. Conclusions: CEA at diagnosis, tumor size, tumor distance from the anal verge, node positivity at diagnosis, and interval from CRT to surgery were predictors of CR. These clinical variables may offer insight into patient selection and timing of treatment response evaluation in the watch-and-wait approach.
- 22 December 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 286
Open AccessPredictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer
Objective: Approximately 10-40% of rectal patients have a complete response (CR) to neoadjuvant chemoradiation (CRT), and these patients have improved survival. Thus, non-operative management (“watch-and-wait” approach) may be an option for select patients. We aimed to identify clinical predictors of complete response following CRT. Methods: Patients treated with definitive chemoradiation for T3-T4, locally unresectable T1-T2, low-lying T2, and/or node-positive rectal cancer from August 2004 to February 2015 were retrospectively reviewed. Most patients were treated with 50.4 Gy radiation and concurrent 5-fluoruracil or capecitabine. Patients were considered to have a CR if surgical pathology revealed ypT0N0M0 (operative management), or if they had no evidence of residual disease on clinical and radiographic assessment (non-operative management). Statistical analysis was carried out to determine predictors of CR and long-term outcomes. Results: Complete records were available on 138 patients. The median follow-up was 24.5 mos. 36 patients (26.3%) achieved a CR; 30/123 operatively managed patients (24.5%) and 6/15 (40%) non-operatively managed patients. None of the 10 patients with mucinous adenocarcinoma achieved a CR. CEA ≥5 μg/L at diagnosis (OR 0.190, 95% CI 0.037-0.971, p=0.046), tumor size ≥3 cm (OR 0.123, 95% CI 0.020-0.745, p=0.023), distance of tumor from the anal verge ≥3 cm (OR 0.091, 95% CI 0.013-0.613, p=0.014), clinically node positive disease at diagnosis (OR 0.201, 95% CI 0.045-0.895, p=0.035), and interval from CRT to surgery ≥8 weeks (OR 5.267, 95% CI 1.068-25.961, p=0.041) were independent predictors of CR. The CR group had longer 3-year distant metastasis-free survival (DMFS) (93.7% vs. 63.7%, p=0.016) and 3-year disease-free survival (DFS) (91.1% vs. 67.8%, p=0.038). 3-year locoregional control (LRC) (96.6% vs. 81.3%, p=0.103) and overall survival (OS) (97.2% vs. 87.5%, p=0.125) were higher in the CR group but this did not achieve statistical significance. CR was not an independent predictor of LRC, DMFS, or DFS. Conclusions: CEA at diagnosis, tumor size, tumor distance from the anal verge, node positivity at diagnosis, and interval from CRT to surgery were predictors of CR. These clinical variables may offer insight into patient selection and timing of treatment response evaluation in the watch-and-wait approach.
- Open Access
- 1 October 2015
- Vol. 6 (5) , 524-533-533
Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
- 1 October 2015
- Vol. 6 (5) , 524-533-533
Open AccessComparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
- Open Access
- 24 April 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 1-7
Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Small cell carcinoma of the rectum is a rare neoplasm with scant literature to guide treatment. We used the Surveillance Epidemiology and End Results (SEER) database to investigate the role of radiation therapy in the treatment of this cancer. The SEER database (National Cancer Institute) was queried for locoregional cases of small cell rectal cancer. Years of diagnosis were limited to 1988–2010 (most recent available) to reduce variability in staging criteria or longitudinal changes in surgery and radiation techniques. Two month conditional survival was applied to minimize bias by excluding patients who did not survive long enough to receive cancer-directed therapy. Patient demographics between the RT and No_RT groups were compared using Pearson Chi-Square tests. Overall survival was compared between patients who received radiotherapy (RT, n = 43) and those who did not (No_RT, n = 28) using the Kaplan-Meier method. Multivariate Cox proportional hazards model was used to evaluate important covariates. Median survival was significantly longer for patients who received radiation compared to those who were not treated with radiation; 26 mo vs. 8 mo, respectively (log-rank P = 0.009). We also noted a higher 1-year overall survival rate for those who received radiation (71.1% vs. 37.8%). Unadjusted hazard ratio for death (HR) was 0.495 with the use of radiation (95% CI 0.286-0.858). Among surgery, radiotherapy, sex and age at diagnosis, radiation therapy was the only significant factor for overall survival with a multivariate HR for death of 0.393 (95% CI 0.206-0.750, P = 0.005). Using SEER data, we have identified a significant survival advantage with the use of radiation therapy in the setting of rectal small cell carcinoma. Limitations of the SEER data apply to this study, particularly the lack of information on chemotherapy usage. Our findings strongly support the use of radiation therapy for patients with locoregional small cell rectal cancer.
- 24 April 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 1-7
Open AccessRadiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Small cell carcinoma of the rectum is a rare neoplasm with scant literature to guide treatment. We used the Surveillance Epidemiology and End Results (SEER) database to investigate the role of radiation therapy in the treatment of this cancer. The SEER database (National Cancer Institute) was queried for locoregional cases of small cell rectal cancer. Years of diagnosis were limited to 1988–2010 (most recent available) to reduce variability in staging criteria or longitudinal changes in surgery and radiation techniques. Two month conditional survival was applied to minimize bias by excluding patients who did not survive long enough to receive cancer-directed therapy. Patient demographics between the RT and No_RT groups were compared using Pearson Chi-Square tests. Overall survival was compared between patients who received radiotherapy (RT, n = 43) and those who did not (No_RT, n = 28) using the Kaplan-Meier method. Multivariate Cox proportional hazards model was used to evaluate important covariates. Median survival was significantly longer for patients who received radiation compared to those who were not treated with radiation; 26 mo vs. 8 mo, respectively (log-rank P = 0.009). We also noted a higher 1-year overall survival rate for those who received radiation (71.1% vs. 37.8%). Unadjusted hazard ratio for death (HR) was 0.495 with the use of radiation (95% CI 0.286-0.858). Among surgery, radiotherapy, sex and age at diagnosis, radiation therapy was the only significant factor for overall survival with a multivariate HR for death of 0.393 (95% CI 0.206-0.750, P = 0.005). Using SEER data, we have identified a significant survival advantage with the use of radiation therapy in the setting of rectal small cell carcinoma. Limitations of the SEER data apply to this study, particularly the lack of information on chemotherapy usage. Our findings strongly support the use of radiation therapy for patients with locoregional small cell rectal cancer.